Azeloprazole (also known as Z-215 or E3710) is a drug under investigation for acid-related medical conditions responsive to suppressing the production of stomach acid. It is considered a member of the proton pump inhibitor class of medications.
Azeloprazole was designed in Japan with pharmacogenomics in mind. Some drugs in the proton pump inhibitor class are metabolized by the hepatic enzyme CYP2C19. Some individuals, such as people of Japanese ancestry, are more likely to be poor CYP2C19 metabolizers; that is, their ability to metabolize certain drugs through CYP2C19 is compromised by a genetic mutation in one or both copies of the CYP2C19 gene that renders the enzyme nonfunctional or less functional. Azeloprazole was designed to avoid CYP2C19 metabolism entirely, thereby avoiding pharmacogenomic issues with poor CYP2C19 metabolizers.[2]
Azeloprazole was designed by the Japanese pharmaceutical company Eisai Co Ltd.[5]
Society and culture
Legal status
In the United States, proton pump inhibitors are found both over the counter and by prescription.[6] However, azeloprazole is not FDA approved in the United States.[7]
Research
Azeloprazole completed phase II clinical trials for erosive esophagitis in Japan in 2017, and phase II clinical trials for GERD in the United States in 2016.[5]
^ abToda R, Shiramoto M, Komai E, Yoshii K, Hirayama M, Kawabata Y (April 2018). "Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers". Journal of Clinical Pharmacology. 58 (4): 425–433. doi:10.1002/jcph.1038. PMID29193126.
^Kodama K, Fujisaki H, Kubota A, Kato H, Hirota K, Kuramochi H, et al. (August 2010). "E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion". The Journal of Pharmacology and Experimental Therapeutics. 334 (2): 395–401. doi:10.1124/jpet.110.167783. PMID20484556.
